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Abstract
Background
Intrabodies are defined as antibody molecules which are ectopically expressed inside the cell. Such intrabodies
can be used to visualize or inhibit the targeted antigen in living cells. However, most antibody fragments
cannot be used as intrabodies because they do not fold under the reducing conditions of the cell cytosol and
nucleus.
Results
We describe the construction and validation of a large synthetic human single chain antibody fragment library
based on a unique framework and optimized for cytoplasmic expression. Focusing the library by mimicking
the natural diversity of CDR3 loops ensured that the scFvs were fully human and functional. We show that the
library is highly diverse and functional since it has been possible to isolate by phage-display several strong
binders against the five proteins tested in this study, the Syk and Aurora-A protein kinases, the αβ tubulin
dimer, the papillomavirus E6 protein and the core histones. Some of the selected scFvs are expressed at an
exceptional high level in the bacterial cytoplasm, allowing the purification of 1 mg of active scFv from only 20
ml of culture. Finally, we show that after three rounds of selection against core histones, more than half of the
selected scFvs were active when expressed in vivo in human cells since they were essentially localized in the
nucleus.
Conclusion
This new library is a promising tool not only for an easy and large-scale selection of functional intrabodies but
also for the isolation of highly expressed scFvs that could be used in numerous biotechnological and
therapeutic applications.
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Abstract
Background: Intrabodies are defined as antibody molecules which are ectopically expressed
inside the cell. Such intrabodies can be used to visualize or inhibit the targeted antigen in living cells.
However, most antibody fragments cannot be used as intrabodies because they do not fold under
the reducing conditions of the cell cytosol and nucleus.
Results: We describe the construction and validation of a large synthetic human single chain antibody
fragment library based on a unique framework and optimized for cytoplasmic expression. Focusing the
library by mimicking the natural diversity of CDR3 loops ensured that the scFvs were fully human and
functional. We show that the library is highly diverse and functional since it has been possible to isolate
by phage-display several strong binders against the five proteins tested in this study, the Syk and Aurora-
A protein kinases, the αβ tubulin dimer, the papillomavirus E6 protein and the core histones. Some of
the selected scFvs are expressed at an exceptional high level in the bacterial cytoplasm, allowing the
purification of 1 mg of active scFv from only 20 ml of culture. Finally, we show that after three rounds
of selection against core histones, more than half of the selected scFvs were active when expressed in
vivo in human cells since they were essentially localized in the nucleus.
Conclusion: This new library is a promising tool not only for an easy and large-scale selection of
functional intrabodies but also for the isolation of highly expressed scFvs that could be used in
numerous biotechnological and therapeutic applications.
Background
Intrabodies are defined as antibody molecules which are
ectopically expressed inside the cell [1,2]. The concept of
using intrabodies can result in the induction of a pheno-
typic knockout either by directly inhibiting the function
of the targeted antigen or by diverting a protein from its
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normal intracellular location [3]. The main advantage of
using intrabodies instead of RNA inhibition is that the
inhibition is done at the protein level. As such, it is possi-
ble to target post-translational modifications or a specific
conformation of the antigen [4]. In addition, by targeting
antibody molecules to specific subcellular compartments
using addressing signals [5], the intrabody induced phe-
notypic knockout can be restrained to a specific cell com-
partment. Altogether, this makes intrabodies a very
promising tool for the study of protein function in vivo [6]
and for the development of highly specific therapies [7].
One of the main problems associated with intrabodies is
that most scFvs are not able to fold under the reducing
conditions of the cell cytosol and nucleus, where most of
the interesting targets are located. This is thought to be
due to the limited stability of scFvs after the two conserved
disulfide bonds are reduced, as occurs in the cell cytosol
[8]. Indeed, in vitro, most of the scFvs cannot be renatured
under reducing conditions [9,10]. To be an efficient intra-
body a scFv must thus present a high in vitro stability [11].
Recent studies using either statistical analyses of scFv
sequences [12] or an experimental approach [13] have
shown that less than 1% of the scFvs are stable enough to
be high quality intrabodies and that only about 10% have
a "moderate chance" to be functional in vivo. In addition,
even if a scFv protein is indeed stable enough in its
reduced form to be expressed and active in vivo, other
parameters such as protease susceptibility [14] or folding
kinetics [10] may also influence the final in vivo fate of the
protein and are critical for intrabody expression and activ-
ity [15].
In order to get an active intrabody it is thus usually needed
to screen several clones in vivo, looking for the best
expressed scFv with a biological activity. In order to facili-
tate this step, it has been proposed to first screen interest-
ing clones using two-hybrid systems before testing them
in cells [12] or even to select them directly in yeast [6].
Several very potent intrabodies have been isolated with
such approaches [16] and this has allowed the isolation of
several highly stable antibody frameworks [13].
As a more general strategy authors have proposed to stabi-
lize scFvs in vivo using a fusion partner like the Maltose
Binding Protein [17] or to construct a scFv library tailored
for intracellular expression [15]. Ideally, such a library
should only contain scFvs able to fold under the reducing
conditions that pertain in the cell cytoplasm. Several
groups have constructed antibody libraries based on a
small number [18,19] or even a single framework [15,20-
22]. In addition, several studies have shown that the
framework stability and folding properties are at least par-
tially conserved upon loop grafting to confer a new specif-
icity. This is both true in the periplasm [23] and in the
cytoplasm [24] of Escherichia coli for scFv and VHH
domains [25]. These findings suggest that it may be possi-
ble to construct a scFv library based on a single optimized
framework for intrabody selection.
We have recently obtained by molecular evolution a
human scFv, called scFv13R4, which is expressed at high
levels in E.coli cytoplasm [26]. This scFv is also expressed
under a soluble and active conformation in yeast [27] and
mammalian cells [3,5,28]. This scFv is very stable in vitro
and can be renatured in presence of a reducing agent. In
addition, analysis of its folding kinetics showed that it
folds faster than the parent scFv and aggregates more
slowly in vitro [10]. The mutations isolated are mainly
located in the VH domain and seem to be highly specific
to this particular scFv since they cannot be transferred to a
very homologous VH domain [29]. Interestingly, most of
these mutations decreased the homology between the
original scFv13 sequence and the intrabody consensus
sequence described by Visintin et al. [30] underlining
again their non-general nature.
In this paper, we have constructed a human scFv library,
based on the framework of the optimized scFv13R4, that
contains more than a billion clones. By using optimized
CDR3 loops and filtering steps to eliminate the non-
expressed clones, we only retained in the library the cyto-
plasmically expressed scFvs without compromising the
diversity, as tested with several proteins used as antigen.
Most of the scFvs in the library are expressed in E.coli and
in mammalian cytoplasm, and are functional as intrabod-
ies. This new library is a promising tool for facile and
large-scale selection of functional intrabodies.
Results
The aim of this project was to construct and validate a
human scFv library, based on a single framework, opti-
mized for intracellular expression and displayed on fila-
mentous phage. To achieve this goal, the following
principles have been used during library construction
(Figure 1a): i) We used the antibody framework of the pre-
viously optimized scFv13R4 human scFv [26]; ii) We
introduced diversity only in the CDR3 loops and mainly
in the H3 region by using degenerate oligonucleotides
[20]; iii) We designed the oligonucleotides so as to have
the same representation of the amino acids as that
observed in natural human CDR3 loops [31,32]; iv) We
removed the non expressed VH and VL sequences by fus-
ing the scFv genes to the CAT enzyme and selecting for
CAM resistance [33,34]. Altogether, these principles
should result in a large fully human synthetic scFv library
optimized for intrabody selection.
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A database of human CDR3 sequences
We compiled human CDR3 sequences from three main
sources: the Kabat database [35], the IMGT database [36]
and the RCSB PDB [37]. After removing the duplicates,
the database contained 6247 H3, 1332 λ CDR3 and 1495
κ CDR3 unique sequences (Figure 1b). It can be noted
that most of the H3 sequences were unique since, for
instance, in the Kabat database, 2703 H3 sequences
(78%) were found only once among the 3469 complete
H3 sequences. The result was comparable in the case of L3
and K3 since, respectively, 74% and 64% of the sequences
were unique in the Kabat database. This underlines the
very high variability of the human CDR3 sequences.
As noted by several authors, this variability is not evenly
distributed in the loop, and the frequency of each amino
acid varies from one position to another and for each loop
length [18,38]. In addition, the amino acid distribution
depends on the animal origin of the antibody sequence
[32]. This bias can be due to a structural constraint as for
instance in the case of the antepenultimate residue which
is frequently an aspartate (D101 using Kabat numbering
scheme) and plays an important role in the switch
between the extended and the kinked conformation of the
H3 [39]. In other cases, this bias may only be due to the
limited number of sequences available for the D and J seg-
ments, and amino acids other than those found in natural
antibodies may be tolerated [40]. For the construction of
the library we decided to make CDR3s that mimic the nat-
ural distribution for two main reasons: i) we wanted the
scFvs generated to be as human as possible for possible
use in human therapy [41]; ii) since the antibodies found
in the database are functional, maintaining their amino
acid distribution will more likely result in functional anti-
bodies, since we incorporated at each position only the
amino acids tolerated in natural antibody CDRs [38].
Library constructionFigu e 1
Library construction. (a) Schematic outline of the steps followed during library construction. The critical steps are: intro-
duction of tailored CDR3 loops in an unique human scFv framework; removal of non-expressed clones by fusion with the CAT 
enzyme and selection on CAM plates; recombination of the 13 VH and 5 VL libraries, and display on phage. (b) Summary of the 
CDR3 loops collected in the database. (c) Distribution of the amino acids at each position of the 5 amino acid long VH CDR3s 
from 55 rearranged human antibodies (D), 43 sequenced clones from the library (E), and predicted from the oligonucleotide 
sequence H3_5 given in additional file 2 (T).
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CDR3 sequences from the database were aligned by
length, and the frequency for each of the 20 possible
amino acids at each position and for each loop length
were calculated. In the case of the light chain CDR3s,
sequences were analyzed independently for each class. In
the case of the H3 sequences, this resulted in 35 tables,
one for each H3 length between 1 and 34 amino acids. For
a loop of length n, this table contained 20 n frequencies.
This is illustrated in figure 1c with the 5 amino acid long
H3 loop case (columns D). The only strongly variable
position was the position 2 where the most frequent
amino acid (Tyr) was only present in 16% of the loops.
This is not surprising since this residue is frequently in
contact with the antigen [42]. By contrast, strong biases
were observed at position 1 (29% of Gly), 4 (45% of Asp
and Gly) and 5 (36% of Tyr). The number of highly vari-
able positions increased with the loop length but, in all
the cases, none of the positions was truly random. For the
other loop lengths, the frequencies are given in additional
file 1 "Amino acid distribution in CDR3s".
Design of the oligonucleotides encoding the CDR3 loops
Eighteen oligonucleotides were designed to follow the
amino acid distribution found in the compiled CDR3
database. We used 192 optimized mixes of the four nucle-
otides at each position of the codon to match as well as
possible the desired amino acid distribution (see [31] and
references therein). Plots showing the target and the oligo-
nucleotide-encoded distributions are given in additional
file 1 "Amino acid distribution in CDR3s". The process is
illustrated in figure 1c with the 5 amino acid long H3
loops. D bars represent the frequencies of the 20 amino
acids in the human database at the 5 positions. T bars are
the expected frequencies with the optimized mixes (after
rounding the nucleotide frequencies at the nearest 5%, see
Methods). Due to the constraint of the genetic code, some
positions were not perfectly optimized. For instance, at
position 3, alanine and glycine were under-represented in
our mix and we had to introduce a substantial amount of
some non naturally found amino acids like cysteine in
order to match other amino acid frequencies. There was
however a good overall agreement between the database
and the oligonucleotide-encoded frequencies since the
most frequently found amino acids were represented in
the library and the rare ones were most of the time present
at a low frequency. The sequences of the 18 degenerate
oligonucleotides used to construct the CDR3 loops are
given in additional file 2 "Sequences of the spiked oligo-
nucleotides used to introduce the random CDR3 loops".
Construction of the library
We constructed independent libraries for each CDR3 loop
length. This was done independently for the heavy and
the two classes of light chains. For each library, random
CDR3 loops were introduced by PCR and the resulting
library cloned back in the scFv13R4 gene fused to the CAT
gene in vector pscFvΔCAT (see below). This resulted in
libraries of scFv13R4 clones with one and only one rand-
omized CDR3 loop.
We validated the approach by first constructing the 5
amino acid long H3 loop library. We sequenced 43 ran-
domly chosen clones and the frequencies of the 20 amino
acids at each of the five positions are shown in figure 1c
(columns E). Some positions diverged from the expected
values as, for instance, the glycine at position 2, which is
over-represented in our library. However, on average, the
distribution in the library matched the expected distribu-
tion. This showed that the quality of the oligonucleotides
was good enough for the approach and that the resulting
library followed the natural distribution of the amino acid
in human H3 loops.
Using this approach, we constructed 13 VH libraries with
H3 loops ranging from 5 to 17 amino acids since more
than 85% of the human H3 lengths are within this range.
The same strategy was used for the VL libraries. We intro-
duced random CDR3 loops of 9 and 10 amino acids mod-
eled on the human κ loops and ranging from 9 to 11
amino acids for those modeled on the human λ loop
sequences. These loop lengths represented respectively
81% and 85% of the human CDR3 loops in the database.
The 18 libraries were constructed and contained at least
3.6 × 106 clones each (Table 1).
Some of these clones, however, may not be functional as
a result of the cloning steps (stop codons present in the
oligonucleotides and PCR) or because of a poor expres-
sion level in the bacterial cytoplasm. To remove these non
functional scFvs, we selected for clones expressed in the
bacterial cytoplasm by means of a fusion between the scFv
and the CAT enzyme [33]. We tested different CAM con-
centrations for this selection step ranging from 15 to 200
μg/ml. At the highest concentration, the library was
indeed enriched in well-expressed scFvs, but also in clones
containing recombined plasmids harboring partial or
complete deletions of the scFv gene (data not shown). We
thus plated the libraries on a medium CAM concentration
(30 μg/ml). This concentration was high enough to
remove all the non-expressed or strongly aggregating scFvs
but did not result in a detectable amount of plasmids har-
boring scFv deletion. The size of the libraries of expressed
scFv was thus estimated as the product of the original
library size (selected on ampicillin) by the frequency of
the CAMR clones. The sizes of the 18 libraries ranged from
2.5 × 106 to 1.9 × 108 (Table 1).
The 18 CAM selected libraries were assembled in amounts
proportional to the natural distribution of CDR3 loop
lengths in human antibodies to give a final library of more
BMC Biotechnology 2007, 7:81 http://www.biomedcentral.com/1472-6750/7/81
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than a billion of clones. Since the theoretical possible
diversity is about 1015 (~13 VH × 107 × 5 VL × 106), it is
very unlikely to obtain twice the same clone in the final
library. One hundred and eighteen clones were sequenced
to determine loop lengths and sequences. As shown in
figure 2, all the introduced lengths except 6 for the H3
were found in the library. 11 and 16 amino acid long H3
loops were under-represented in the library. This is pre-
sumably due to the poor quality of these oligonucleotides
as shown by their profile on an Agilent Bioanalizer (data
Table 1: Diversity of the CDR3 libraries
CAM phenotypeb
Initial diversitya ++ + - final diversityc
H3-5 1.4e8 15/20 3/20 2/20 1.1e8
H3-6 2.7e7 20/20 0/20 0/20 2.7e7
H3-7 9.2e7 16/20 3/20 1/20 7.4e7
H3-8 5.0e6 14/20 4/20 2/20 3.5e6
H3-9 2.4e8 16/20 1/20 3/20 1.9e8
H3-10 1.0e7 10/20 6/20 4/20 5.0e6
H3-11 2.2e7 9/12 1/12 2/12 1.7e7
H3-12 1.0e7 15/20 2/20 3/20 7.5e6
H3-13 2.3e7 8/12 3/12 1/12 1.5e7
H3-14 1.0e7 12/20 4/20 4/20 6.0e6
H3-15 2.1e7 8/12 3/12 1/12 1.4e7
H3-16 1.0e7 12/20 2/20 6/20 6.0e6
H3-17 1.1e7 12/20 4/20 4/20 6.6e6
K3-9 3.6e6 11/16 1/16 4/16 2.5e6
K3-10 4.4e6 10/16 1/16 5/16 2.8e6
L3-9 1.7e7 11/20 6/20 3/20 9.4e6
L3-10 1.5e7 10/20 9/20 1/20 7.5e6
L3-11 1.8e7 15/20 3/20 2/20 1.4e7
a Initial diversity of the library cloned as fusion with CAT and selected on ampicillin. This is the number of clones obtained after transformation.
b Between 12 and 20 clones from the transformation were checked on CAM plates. Plates were incubated for 16 h at 37°C and colony size 
estimated. Columns ++,+ and - give, respectively, the fraction of clones that grew normally, gave tiny colonies, and did not grow at all.
c Diversity of the libraries selected on CAM. The diversity is estimated from column "Initial Diversity" and "CAM phenotype" by assuming that the 
final diversity is close to (Initial Diversity) × (CAM phenotype ++). The real diversity may be a higher since some of the clones noted + in column 
"CAM phenotype" may be present in low abundance.
CDR3 length distributionFigure 2
CDR3 length distribution. Distribution of the CDR3 lengths in the database and in 118 sequenced clones from the library 
(see additional file 3: Sequence of randomly picked clones).
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not shown). H3 loop lengths ranging from 7 to 12 were
over-represented in the library but only by a two-fold fac-
tor. The H3 loop lengths between 8 and 17 amino acids,
which are the most frequently found in human antibod-
ies, were all present in the library. The number of
sequenced clones was too small to analyze the frequency
of the amino acids found in the CDR3 loops. Except for
some contaminations with the original scFv13R4
sequence (4% for H3), no CDR3 sequence was found
twice in the sequenced clones. The sequences of the 118
clones are shown in the additional file 3 "Sequence of ran-
domly picked clones".
Cytoplasmic expression of scFvs
The idea underlying the library construction is that the
CAM selection step of the VH and VL libraries should
result in only expressed scFv proteins. Indeed, since only
the CDR3 loops are modified between scFv13R4 and the
libraries, most of the interface residues between the two
domains are conserved between clones [43]. It is thus
likely that any VH will assemble correctly with any VL and
that the expression level of the resulting scFv will be close
to that of both clones from the VH and VL libraries
selected on CAM. We tested this hypothesis by picking
random clones of the final library and expressing them in
E.coli cytoplasm and in mammalian cytosol.
Twenty clones were tested in E.coli and 19 of them showed
some soluble expression in the cytoplasm (Figure 3).
One-fourth of the clones (5/20; clones 3, 10, 11, 16, 19)
were expressed at very high levels since the scFvs were
clearly visible on a Coomassie stained gel. To obtain a
more global view of the soluble expression levels in E.coli,
the library was cloned in front of the GFPuv gene under
the control of the T7 promoter. If the scFv is soluble and
expressed in the cytoplasm, this should result in GFP
activity that can be directly monitored on an UV transillu-
minator [44,45]. About 1000 clones were tested for the
presence of detectable GFP activity and approximately
60% exhibited a GFP+ phenotype (data not shown) show-
ing again that most of the scFv clones from the library
were expressed in E.coli cytoplasm.
We next tested the expression of the library in mammalian
cells. Fifteen scFvs were cloned in a mammalian expres-
sion vector as fusions with the EGFP gene and under the
control of the SV40 early promoter, then transfected in
HeLa cells. Typical results are shown in figure 4. Three
clones were expressed at a high soluble level, comparable
to that of the parental scFv13R4 (clone 15), 10 scFvs were
found to be mainly soluble but some aggregated material
was still present in the cell (clones 33 and 36) and 2
clones accumulated essentially as cytoplasmic aggregates
(clone 24), as observed with the hybridoma-derived anti-
oncoprotein E6 scFv 1F4 (Figure 4) [28]. In conclusion,
thirteen out of the fifteen scFvs tested were expressed as
soluble proteins that could be easily detected in the cyto-
plasm and in the nucleus of the transfected cells.
Altogether these results showed that more than 85% of
the clones from the final library expressed soluble scFv in
E.coli (16/20) and mammalian cytoplasm (13/15), while
about 20% of them expressed scFv at a very high level (5/
20 in E. coli and 3/15 in eucaryotic cells). This is a great
improvement over the results obtained by other authors
with non optimized scFv libraries [12].
Selection of binders
As shown above, the library contains a high proportion of
expressed clones but it remains to be shown that antibod-
ies against particular proteins can be selected. We thus
used the phage displayed library to select for binders
against five different antigens using purified proteins
adsorbed on microtiter plates. We performed three rounds
of selection and the eluted phages were tested by ELISA
against the immobilized antigens. As shown in figure 5a,
in all the cases a positive signal was obtained after a single
round of selection. This signal increased strongly after two
rounds and did not increase further during the third
round of selection. This very fast selection process was
presumably due both to the focused library itself, which
contains only expressed scFvs resulting in a low back-
ground, and to the use of a trypsin-sensitive helper phage
that further decreased the background level [46,47].
We next tested whether the library contained clones
expressing soluble scFvs in the periplasm. The non-sup-
pressive HB2151 strain was infected with the phages
eluted after the third round of selection against tubulin,
GST:Syk and the core histones. Periplasmic extracts were
prepared and tested for binding activity by ELISA (Figure
5b). In the three cases, 12–20% of the clones gave a strong
signal with absorbance values higher than 0.5 (10 times
the background) and about 30% were clearly positive
with an absorbance value higher than 0.1 (twice the back-
ground). These results compared favorably with those
reported with other scFv libraries, underlining again the
high proportion of well-expressed clones present in the
library. In addition, this showed that our CAT fusion
approach selected efficiently for constructs without stop
codons present in the oligonucleotides. This is indeed of
premium importance to isolate soluble scFvs from phage-
displayed libraries since amber stop codons in CDRs are
frequently selected during panning of synthetic and semi-
synthetic libraries [48].
In both the previous characterizations, the scFvs were
expressed under oxidizing conditions in E.coli periplasm,
either as scFv-pIII fusion or as soluble protein. In addi-
tion, panning was done on phage, again under oxidizing
BMC Biotechnology 2007, 7:81 http://www.biomedcentral.com/1472-6750/7/81
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conditions. We could not exclude that the selection and
the screen introduced a bias towards clones expressed in
the periplasm at the expense of those expressed in the
cytoplasm. To test that the selected scFvs were indeed also
expressed in the cytoplasm, we subcloned the same pool
of clones (round 3) in a cytoplasmic expression vector
under the control of the strong T7 promoter. For each
antigen, ninety-five clones were tested by ELISA for bind-
ing to their respective antigen. In each case, the number of
positive clones was comparable or even better than in the
periplasmic screen (Figure 5b). For instance, in the case of
GST:Syk, 80% of the tested clones were positive after three
rounds of selection. This demonstrated that the periplas-
mic selection step did not decrease the proportion of sol-
uble scFvs in the cytoplasm and that by using our library
it is not necessary to directly select within the cytoplasm
to avoid introducing a bias during the selection [13].
We sequenced individual clones from the 2nd and the 3rd
round of selection against tubulin (Table 2). Most of the
clones were different since only one clone from the 2nd
round and one from the 3rd round were found twice. This
demonstrated that a high diversity is still present after 3
rounds of selection. Eight of the anti-tubulin scFvs were
purified by affinity chromatography from the cytoplasm.
In all cases, more than 8 mg of scFv was purified from one
liter of cells grown in a flask (OD600 = 5), and some scFvs
were expressed at a level per cell comparable to the excep-
tionally high expression level reported for an anti-HER2
in E. coli periplasm (Table 2) [49]. This expression level
corresponds to about 1/4th of that of the original
scFv13R4 but this may be presumably increased by using
optimized protocols.
Functionality of isolated scFvs as intrabodies
To determine if the isolated scFvs were able to bind to
their target in vivo we characterized the anti-histones scFvs
expressed in human cells. The third round of selection was
cloned in vector p513-EGFP and ten randomly chosen
clones were transfected in HeLa cells. Typical results of the
cells expressing the scFv-EGFP fusions and observed by
fluorescence microscopy are shown in figure 6. One scFv
was expressed as cytoplasmic aggregates. Four scFvs were
expressed as soluble cytoplasmic proteins, as judged by
the homogeneous staining of the cells, at a level compara-
ble to that of the scFv13R4. Finally, three scFvs gave rise to
a strong staining of the nucleus (clones 2, 6 and 9) and,
two scFvs were exclusively localized in the nucleus (clones
5 and 10). Since these scFvs fused to the EGFP were
expressed in the cytoplasm of the cell and did not contain
a nuclear localization signal, this suggested that they were
able to interact in vivo with the histones and were thus
active inside the cell [5]. This analysis showed that about
half of the clones present after the third round of selection
against core histones were able to bind to their nuclear tar-
get in vivo. This was confirmed in vitro by western and dot
Expression in E. coli cytoplasmFigure 3
Expression in E. coli cytoplasm. Twenty clones from the 
library were cloned in a cytoplasmic expression vector and 
expressed in E.coli under the control of the T7 promoter. 
Soluble extracts were prepared, separated by SDS-PAGE, 
and analyzed by Coomassie staining (a) or Western-blot (b) 
using 9E10 and an alkaline phosphatase conjugated anti-
mouse IgG antibody (substrate BCIP/NBT). Each lane corre-
sponded to 2 × 107 cells. The arrow on the left indicates the 
position of the scFv.
Expression of randomly picked scFvs in HeLa cellsFigure 4
Expression of randomly picked scFvs in HeLa cells. 
Cells were transfected with scFv-EGFP constructs as indi-
cated. 13R4 and 1F4 represent the positive and negative con-
trols, respectively [5]. At 24 h post-transfection, cells were 
fixed and visualized under a fluorescent microscope with the 
fluorescein isothiocyanate filter set. The micrographs repre-
sent typical fields containing a similar number of cells in each 
case. Magnification: × 400.
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blot with purified scFv (additional file 4 "In vitro charac-
terization of some anti-histones scFvs"). In addition,
sequencing of the five positive clones showed that they
contained different heavy and light chain CDR3 regions
(additional file 4 "In vitro characterization of some anti-
histones scFvs").
In vitro characterization of anti-tubulin scFvs
To demonstrate the activity of the anti-tubulin scFv under
the reducing conditions that pertain in the cell cytoplasm,
we extracted the scFvs in presence of a reducing agent and
we compared the ELISA signal with that obtained with the
scFvs extracted under oxidizing conditions. As shown in
figure 7, the five scFvs gave the same ELISA signal in both
conditions, demonstrating the full activity of the scFvs
under reducing conditions and thus in absence of
disulfide bond formation.
The five scFvs were able to recognize unfolded tubulin by
western blot in brain extracts and the native protein in a
competition ELISA (data not shown). Finally, we tested
their ability to interact with microtubules in cells by IF.
Clones 2F12C and 2G4C, but no the three other scFvs,
were able to reveal the microtubule network in cells. In
figure 8 is illustrated the utility of this new library as a
source for both in vivo and in vivo proteomic studies: HeLa
cells were transfected with the anti-histones clone 5 fused
to a Red-GFP then the microtubule network was revealed
by IF using the 2F12C scFv.
Finally, we characterized clone 2F12C by Biacore since it
was the best binder in ELISA and IF. Data were fitted to a
two-state reaction model giving a Kd of 50 nM (additional
file 5 "Biacore analysis of clone 2F12C"). This value is
comparable to those obtained for the best scFvs obtained
with other single framework libraries with variability
restrained to the CDR3 loops [20,22].
Altogether, our results show that the library described in
this report is highly diverse and functional and allows fast
and easy isolation of in vivo and in vitro active fully human
intrabodies.
Discussion
As noted by several authors [6], despite very interesting
applications in the proteomic [19] and therapeutic fields
[7], intracellular immunization remains a difficult
approach, and its full potential in the post-genomic area
remains to be demonstrated. The usual approach to
obtain efficient intrabodies requires two successive steps.
First, a panel of antibodies against the target antigen must
be isolated. Due to the availability of very high quality
naive antibody libraries displayed on phage, this step is
now easily accomplished by phage-display and can be
automated in order to isolate binders against several pro-
teins in parallel [50]. In a second step, these antibody frag-
ments (scFv or Fab) must be tested in vivo for their ability
to inhibit their target. However, most scFvs do not fold
properly under the reducing conditions that pertain in the
cytosol and the nucleus of the cell where most of the inter-
esting targets are located. This results in the formation of
aggregated and inactive scFvs, unable to interact with their
target. This makes the process of identifying intrabodies
from regular scFv libraries a difficult procedure even when
the screening is done in vivo using two-hybrid system [12].
In addition, this low proportion of active scFvs in the cur-
rent libraries makes the isolation of intrabodies against
different epitopes of the same protein at best difficult if
not impossible. More recently, to avoid this two-step pro-
cedure, Visintin and collaborators [6] demonstrated that it
is possible to directly select, in a single step, efficient intra-
bodies in yeast using the two-hybrid system. However, the
relatively low efficiency of yeast transformation restrained
the size of the library to 107.
In this report we describe the construction and use of a
large phage displayed library of scFvs optimized for intra-
cellular expression. The library was constructed on a sin-
gle antibody framework previously evolved to improve its
activity inside the cytoplasm [26]. The parental scFv is very
stable, has favorable folding and aggregation kinetics [10]
and is expressed at very high levels in all tested cell types
[5,26,27]. Having a single framework for the construction
of a library should allow more comparable expression lev-
Selection of binders against five purified proteinsFigure 5
Selection of binders against five purified proteins. (a) 
2.5 × 1010 phages from each round of selection were tested 
by ELISA against their respective antigen and revealed using 
an anti-M13 HRP conjugated monoclonal antibody (Pharma-
cia). R0 is the non selected library and Rn the stock obtained 
after the nth round of selection. Specificity was tested on BSA 
for the 3rd rounds of selection (A450 nm ~0.1 – 0.3). (b) Per-
centage of soluble active scFvs (Absorbance > 0.1) selected 
after three rounds against the indicated protein and 
expressed either in the periplasm (gray) or in the cytoplasm 
(black).
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els between clones since most of their sequences are con-
served. In addition, because CDR sequences play also a
role in scFv folding and expression, we anticipated that
the expression level of the clones would still exhibit some
variability. To minimize these differences, we only intro-
duced variability in the CDR3 loops for three main rea-
sons: these loops are the most variable in antibodies and
are thus more likely to be highly tolerant to sequence and
length variations; the parental scFv had gained mutations
in the CDR2 loops during its evolution process and we did
not want to reverse back these mutations; it has been pre-
viously shown that introduction of variability in the
CDR3s was enough to generate antibodies against most
proteins [19]. In addition, the frequencies of the amino
acids in these loops were carefully biased so as to recover
the distribution observed among natural human
sequences. When the expression levels of randomly
picked clones were compared in the cytoplasm, despite
some clear differences, a high proportion of them were
correctly expressed at high levels both in E.coli and in
mammalian cells (Figures 3 &4).
It must be noted that the design of the library allowed in
the VL not only the introduction of CDR3s corresponding
to the original λ light chain class but also to the κ class.
Such a hybrid VL domain with full binding properties has
been previously realized by grafting λ CDRs on a κ frame-
work [11], and we have also successfully grafted the CDRs
from a mouse κ scFv directed against the human papil-
loma virus E6 protein [44] on the scFv13R4 λ framework
(manuscript in preparation). This is the case of the best
isolated anti-tubulin 2F12C scFv since it contains a κ
CDR3 close to the CDR3 sequence encoded by human
germline IGKV1-16 [36]. This showed that such grafts can
produce functional scFv and that the differences in the
sequences of the CDR3 loops between the λ and the κ
classes are due to evolutionary divergences and not to
structural constraints.
A frequent concern when constructing scFv libraries is the
simultaneous optimization of the library's diversity and
size. Indeed, the size of such a library is limited by the
transformation efficiency to about 1010 clones. Given this
"limited" number of clones, it is thus of premium impor-
tance to avoid non-expressed scFvs or duplicates. To solve
this problem we used a two-step procedure. First, we con-
structed 18 "small" libraries for each CDR3 length (13 VH
and 5 VL) and removed from them all the non-expressed
clones by fusion to the CAT enzyme, in E.coli cytoplasm,
and selection on CAM plates. This step reduced each
library diversity by about 10–30%. In a second step we
recombined the selected VH and VL libraries at random to
generate the final diversity. We made the assumption that
if a VH and a VL were expressed when associated respec-
tively with the VL13R4 and the VH13R4, the scFv consti-
tuted with these VH and VL would also be expressed,
Table 2: Sequences of some anti-tubulin scFvs
VH CDR3 VL CDR3
Name Sequence length Sequence length frequencya yieldb WBc IFd
Round 2
C12C SSITIFGGGM
DV
12 HSREVHRTF 9 1/5 19
E12C SGGNTFDY 8 QQYYRKPW
T
9 1/5 53
F1C GNADGGEN
WELFDK
14 QLYQNTLW
T
9 2/5 52
H6C SSITIFGGGM
DV
12 QQNWTSPL
S
9 1/5 nd
Round 3
2C1C RGRDY 5 QQYNTSPFS 9 1/6 8.6 + -
2E11C GRNVLNY 7 QQNSSSPRF
T
10 2/6 8.7 + -
2F12C GRRALGN 7 QQYNTSPFS 9 1/6 45 + +
2G4C GRRALGN 7 LTWSMRSAI 9 1/6 15 + +
2G9C GRRALGN 7 LTTENSVYRL
V
11 1/6 50 + -
Sequences of the CDR3s of the best positive clones in an ELISA using cytoplasmically expressed scFv from the 2nd (5 clones) and the 3rd (6 clones) 
round of selection (Table 2). a Frequency of apparition of the scFv among sequenced clones of the same round. b Yield: mg of scFv purified from 1 
liter of cells grown in a flask (OD600 = 5). c WB: detection of tubulin in brain extracts by Western blot. d IF: + means that the scFv is able to reveal 
microtubule network by Immunofluorescence (Fig. 8). The sequences of the clones 2C1C, 2E11C, 2F12C, 2G4C and 2G9C have been submitted to 
the EMBL database and their accession numbers are respectively AM886280, AM886281, AM886282, AM886283 and AM886284.
BMC Biotechnology 2007, 7:81 http://www.biomedcentral.com/1472-6750/7/81
Page 10 of 17
(page number not for citation purposes)
resulting in a library containing only expressed scFvs. As
shown in figure 3 this is indeed the case since 19 out of 20
clones picked at random were expressed at least partially
under a soluble form in E.coli cytoplasm. Since this selec-
tion step was done early during the library construction,
the diversity of the final library was only limited by the
final transformation. In addition, this recombination
step, by generating a high diversity, ensured that all the
clones were unique in the final library. Altogether, this
approach resulted in a library of 1.5 billion expressed
scFvs.
Successful use of scFvs as intrabodies on a large scale
requires several essential points to be fulfilled by the
library. First, the scFv must be easy to isolate. This is the
case here since we were able to isolate binders against all
the tested proteins (Figure 5a). Second, the scFv should be
able to fold in all the cell compartments, particularly in
the reducing ones. Again, this is the case for the scFv
library described herein, since more than 80% of the
tested clones are at least partially soluble in the cell (Fig-
ure 3 &4). In addition, we have shown that good cytoplas-
mic binders can be obtained from the phage selected scFvs
in E.coli (Figure 5b) and in eukaryotic cells (Figure 6).
Finally, to get active intrabodies it is important to be able
to target any epitope of a protein. It is know that the
immune system is able to raise antibodies against essen-
tially any part of the surface of a protein [51], and it
remains to be proved that this is also the case with our and
other phage displayed libraries. However, the high length
diversity introduced in the CDR3 loops should favor a
broad diversity of paratope shapes [52] and thus of the
epitopes recognized.
Even if the library has been tailored for the isolation of
intrabodies, it can also be used as a general purpose
library to select scFvs for diagnostic and therapeutic appli-
cations. Because we designed the CDR3 diversity using
expressed human sequences, the scFvs present in the
library are fully human and should not induce an anti-
scFv antibody response in patients [41]. However, for
such applications, the affinity of the scFv for its target
must be very high in order to get a good sensitivity in a
diagnostic test or a strong in vivo effect in therapy. Since
our library is based on a single framework, it should be
Expression of anti-histones scFvs fused to EGFP in HeLa cellsFigure 6
Expression of anti-histones scFvs fused to EGFP in 
HeLa cells. The cells were transfected and treated as indi-
cated in the legend of figure 4. The pictures represent typical 
cells transfected with scFv13R4 and three representative 
anti-histones clones (2, 5 and 10). D, DAPI staining (blue) 
merged with the GFP signal.
Activity of scFvs under reducing conditionsFigure 7
Activity of scFvs under reducing conditions. Extracts of 
cells expressing the scFvs in the cytoplasm were prepared as 
in figure 3 in presence or absence of 10 mM DTT. ELISA was 
performed in presence or absence of DTT, accordingly. x-
axis: amount of extract per well. y-axis: ELISA signal at 450 
nm.
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fairly easy to improve the affinity of a selected scFv by
using, for instance, chain shuffling [53], error-prone
mutagenesis [54] or by optimization of the CDR1 and
CDR2 loops [20].
Conclusion
This new library is a promising tool not only for an easy
and large-scale selection of functional intrabodies but also
for the isolation of highly expressed scFvs that could be
used in numerous biotechnological applications. The
availability of scFvs based on a highly stable framework
[10] that are obtainable from E. coli in milligram quanti-
ties from a 10 ml culture (Table 2) would be very useful
for developing antibody arrays. Because of the human ori-
gin of both the framework and binding site regions [41],
scFvs isolated from the library should also have therapeu-
tic applications.
Methods
Bacterial strains, chemicals and enzymes
LB and 2xYT media were previously described [55]. Strain
C-Max5αF' (Bio-rad laboratories) is E.coli K-12, [F' lacIq
Tn10] φ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1
hsdR17(rk- mk+) phoA supE44 λ- thi-1 gyrA96 relA1.
MC1061 (ATCC #53338) is E.coli K-12, F- λ- hsdR2 hsdM+
hsdS+ mcrA mcrB1 araD139 Δ(ara-leu)7696 Δ(lac-
IPOZY)X74 galE15 galU galK16 rpsL thi. Non-suppressor
strain HB2151 is E. coli K-12 [F'proA+B+lacIq lacZΔM15]
ara Δ(lac-pro) thi. Chemicals were purchased from Sigma.
Restriction enzymes and cloned Taq polymerase were
from Fermentas. ProofStart and Pfu DNA polymerases
were respectively purchased from Qiagen and Promega.
Plasmid DNA, PCR and agarose separated DNA were puri-
fied using Macherey-Nagel Nucleospin kits.
Oligonucleotides
The sequences of the 18 spiked oligonucleotides used to
introduce degenerate CDR3 loops and listed in the addi-
tional file 2 "Sequences of the spiked oligonucleotides
used to introduce the random CDR3 loops" have been
synthesized and HPLC purified by IBA GmbH (Goettin-
gen, Germany). Other oligonucleotides were synthesized
by MWG:
T7.back CCGGATATAGTTCCTCCTTT;
T7.for CTGCTAACCAGTAAGGCAAC;
M13rev-49 GAGCGGATAACAATTTCACACAGG;
M13uni-43 AGGGTTTTCCCAGTCACGACGTT;
scFvCAT.rev AACGGTGGTATATCCAGTGA;
scFvCAT2.rev CGGTGGTATATCCAGTGATTTTT;
PliaisonH3 TGGGGCAGAGGCACCCT;
PliaisonH3.back AGGGTGCCTCTGCCCCA;
PliaisonL3 GCAGTAATAATCAGCCTCGTCC
Plasmids
Phagemid vector pCANTAB6 [56] was used for N-termi-
nal fusion of NcoI/NotI-scFv fragments to the minor coat
protein pIII of filamentous phage M13. This phagemid is
derived from pUC119 and contains in the following
order: a lac promoter, the pelB leader sequence, NcoI and
NotI sites for scFv cloning, a His6 and a c-myc tag recog-
nized by the 9E10 monoclonal antibody [57], an amber
codon and the pIII gene sequence.
For cytoplasmic expression of the scFvs in E.coli we used
plasmid pET23NN [58]. This plasmid is derived from
pET23d(+) (Novagen) and contains a T7 promoter, fol-
lowed by a NcoI site containing the ATG initiator, a NotI
site followed by a c-myc and a His6 tag.
Plasmid pscFvΔCAT is derived from pTrc99A and contains
a tac promoter, followed by a NcoI site containing the ATG
initiator of an out-of-frame scFv, a NotI site followed by
the CAT gene. When a scFv is inserted within the NcoI-NotI
sites, the scFv is expressed as a fusion with the CAT pro-
tein. The construction was done as following. First, the
unique BstEII site of pTrc99A (A13038) was removed by
digestion followed by 5' overhang fill-in, to form blunt
ends, and ligation. The resulting plasmid was digested
with NcoI and NotI, and the 4210 bp fragment purified
(fragment I). Second, the unique NcoI site of plasmid
pACYC184 (X06403) located within the CAT gene was
removed by site directed mutagenesis by changing the
Thr172 codon from ACC to ACG. Then the CAT gene was
amplified by PCR using CAT-NotI.for (TAAGGCGGCCG-
CAATGGAGAAAAAAATCACTG) and CAT-HindIII.back
(ACTGCCTTAAAAAGCTTACGCC). In the oligonucle-
otide sequences, the introduced restriction sites are under-
lined and the beginning and the end of the CAT gene are
in bold-italic. The 660 bp PCR fragment was digested by
NotI and HindIII, and purified (fragment II). Third, a 750
bp NcoI-NotI scFv13E6 fragment, a grafted version of the
scFv13R4 containing the CDR loops of an anti-E6 mono-
clonal antibody (Philibert et al., to be published), was
purified (fragment III). Four, the three fragments I, II and
III were ligated to give plasmid pscFvCAT. Finally, an
internal deletion of 165 bp was introduced in the scFv by
removing the fragment between the two PstI sites of the
gene. The resulting plasmid, called pscFvΔCAT, is AmpR
and CAMS since the deletion of the PstI fragment resulted
in a frameshift in the scFv.
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Plasmid p513-EGFP is a derivative of pSG5 [59] and har-
bors the EGFP coding region (Clontech) under the control
of the SV40 early promoter. The p513-scFv-EGFP con-
structs correspond to in frame fusions of the scFvs and the
EGFP coding region with a linker of 10 residues. The scFv
coding regions were amplified with oligonucleotide prim-
ers 5'-ACTGATAAGCTTGCCACCATGGCCGAGGTGC
and 5'-TTGATTACTAGTGAGTTTTTGTTCTGCGGCC and
inserted into the HindIII-SpeI digested p513-EGFP vector.
Database of CDR3 sequences
We used the release 5 (August, 1992) of the Kabat data-
base [35]. This dataset contained 44990 sequences. We
extracted the 4643 human VH sequences which were not
a pseudogene and were not humanized. H3 sequences
were then extracted from this dataset taking first into
account the nucleotide sequence when present then the
amino acid sequence. Finally we kept the 3469 complete
H3 sequences that contained only the 20 regular amino
acids, among which 2703 were unique. The same proce-
dure was followed for λ and κ light chains, respectively,
resulting in 1044 and 1291 sequences from which 775
and 828 were unique.
We also extracted CDR3 sequences from the IMGT/LIGM-
DB database the 27 Nov. 2003 [36]. We considered only
the "productive/regular/human/cDNA+RNA/Rearranged"
genes. We obtained 5179 H3, 1432 K3 and 1131 L3
sequences from which 4323, 974 and 812 were unique.
We collected 127 additional human antibody sequences
from the Protein data bank [37]. For this we used the file
of 510 sequences already compiled by Andrew Martin the
19 August 2003 [60]. The complete list of CDR3
sequences is available on request to PM.
Spiked oligonucleotide design
In biasing the representations of the amino acids, opti-
mized mixtures of the nucleotides at each of the three
codon positions were calculated as described previously
[31,61]. Premature termination of protein sequences was
limited by imposing and upper bound of 0.05 on the
probability of realizing a stop codon. For the 34 positions
which did not satisfactorily recover the desired probabili-
ties of the amino acids, a second optimization was done
with the same method but with no constraint on the stop
codon frequency. For oligonucleotide synthesis, the calcu-
lated frequencies were rounded in increments of 5% as
follows: all the frequencies between 0% and 5% were
rounded to 5%; other frequencies were rounded to the
nearest 5%; if the resulting sum was higher than 100%,
5% was removed from the rounded amino acid frequency
larger than 5% for which the difference between the
rounded and the target frequency was maximal and the
process iterated until the sum was 100%; if the sum was
lower than 100%, 5% was added to the rounded fre-
quency lower than 95%, for which the difference between
the rounded and the target frequency was maximal and
the process iterated until the sum was 100%. The
sequences of the oligonucleotides are given in the addi-
tional file 2 "Sequences of the spiked oligonucleotides
used to introduce the random CDR3 loops".
Construction of VH and VL libraries
Variable CDR3 sequences were introduced in scFv13R4 by
PCR assembly using a hot-start proofreading polymerase
(ProofStart, Qiagen) using as template plasmid pAB1-
scFv13R4p [10]. To introduce random H3 loops, the 5' of the
gene with the random H3 sequence was obtained with oligo-
nucleotides M13rev-49 and one of the 13 degenerate oligo-
nucleotides (H3_n, see additional file 2: Sequences of the
spiked oligonucleotides used to introduce the random
CDR3 loops) and the 3' with PliaisonH3 and M13uni-43
(both for 20 cycles at 55°C). The two purified bands were
thus assembled by PCR (30 cycles, 55°C) using M13rev-49
and M13uni-43. The resulting PCR was purified using a com-
mercial kit (Nucleospin, Macherey-Nagel), digested for 16 h
at 37°C with NcoI and NotI enzymes, then purified on gel.
The same procedure was followed to introduce random L3
and K3 loops except that the pairs of primers were M13rev-
49/PliaisonL3 for the 5' and one of the degenerate oligonu-
cleotide encoding the L3/K3 loop (K3_n or L3_n, see
oligo.txt) with M13uni-43 for the 3' part of the gene.
Each digested band was ligated for 16 h at 16°C with 1 μg of
NcoI-NotI digested and purified pscFvΔCAT in 100 μl using
10 Weiss units of T4 DNA ligase. The ligation was heat inac-
tivated and purified using a commercial kit (Nucleospin).
The ligation was then electroporated in 300 μl of MC1061
competent cells [62] and plated on a 600 cm2 square plate of
LB containing 100 μg/ml of ampicillin and incubated for 16
h at 37°C. The 21 libraries (13 VH and 5 VL) were scrapped
in 10 ml of LB with 10% glycerol and 109 bacteria were
immediately plated on a 600 cm2 square plate of LB contain-
ing 100 μg/ml of ampicillin, 1 mM IPTG and 30 μg/ml of
CAM and incubated for 16 h at 37°C. The 21 libraries were
scrapped in 10 ml of LB with 10% glycerol and frozen at -
80°C. An aliquot was used to prepare DNA for the library
assembly.
Library assembly
The 13 VH libraries were amplified using primers M13rev-
49/PliaisonH3.back using Pfu polymerase and the 5 VL
libraries using scFvCAT.rev/H3_Liaison (30 cycles, 55°C).
The 21 PCR bands were purified then carefully quantified
on gel using ImageJ software [63]. The 13 VH bands were
pooled in amounts proportional to their frequency in
human H3. This mix is called VHpool. The 2 VL κ bands
were pooled in order to obtain 75% of 9 amino acids and
25% of 10 amino acids loops. The VL λ bands were pooled
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to obtain 30% of 9, 30% of 10 and 40% of 11 amino acids
loops. Finally the κ and λ mixes were pooled in order to get
50% of each class in the final mix called VLpool.
VHpool and VLpool were assembled by PCR using Taq
DNA polymerase and primers M13rev-49/scFvCAT2.rev
in 500 μl (30 cycles, 55°C). The PCR was successively
digested with 20 units of NcoI and NotI for at least 6 h
each, purified then quantified on gel. 50 μg of vector
pCANTAB6 was successively digested with 80 units of
NcoI and NotI for at least 6 h each, purified then quanti-
fied on gel. 5 μg of linearized pCANTAB6 was ligated with
an equal molar amount of insert (0.84 μg) in 500 μl at
16°C using 50 Weiss units of T4 DNA ligase. The ligation
was heat inactivated and purified using a commercial kit
(Nucleospin). The purified ligation was then electropo-
rated in 10 × 300 μl of C-Max5αF' competent cells [62],
plated on ten 600 cm2 square plate of LB containing 1%
of glucose and 100 μg/ml of ampicillin. After incubation
for 16 h at 37°C, cells were scrapped in 2xYT containing
10% of glycerol and kept frozen at -80°C in aliquots cor-
responding to twenty times the diversity.
Antigens
Aurora-A is an His-tagged protein produced in E.coli.
GST:Syk was expressed in E.coli and was a gift from P. Dar-
iavach [64]. E6 protein from papillomavirus HPV16 was
expressed in cyanobacterium Anabaena (Desplancq et al.,
to be published). Histones (a mix of H2a, H2b, H3 and
H4) were purchased from Sigma (type II-AS. #H7755).
Tubulin was purified from pig brain [65].
Library rescue and selection
Library rescue was done essentially as previously described
using a trypsin sensitive helper phage [66]. Briefly, an aliquot
of the library corresponding to a 10 to 20 fold excess over the
diversity (2–3 × 1010 bacteria) was inoculated in 1000 ml of
2xYT containing 100 μg/ml ampicillin and 1% glucose and
grown with shaking at 37°C until OD600nm was 0.7. 200 ml
(~3 × 1010 cells) were infected with 5 × 1011 helper phage
KM13 [66] and incubated without shaking for 30 min at
37°C. Cells were pelleted, resuspended in 1000 ml of 2xYT
containing 100 μg/ml ampicillin and 25 μg/ml kanamycin
and incubated overnight with vigorous shaking at 30°C. The
supernatant containing phages was precipitated twice by
adding 1/5th of the volume of PEG-8000 20%, NaCl 2.5 M,
resuspended in PBS supplemented with 15% of glycerol and
aliquots containing 1011-1012 phages were stored at -80°C.
To select for binders, 100 μl of purified antigens were coated
in a Nunc Maxisorp 96-well plate. For the first round we used
an antigen concentration of 10–100 μg/ml and 1–10 μg/ml
for the subsequent rounds. Plate was washed 3 times with
PBS containing 0.1% of Tween20 (PBST) and saturated 2 h
at RT with PBS containing 2% of non fat milk (MBPS). 1011-
1012 phages were added per well in 2% MPBS and incubated
for 2 h at RT. The plate was washed 20 times (first round) or
40 times (2nd and 3rd rounds) with PBST then 3 times with
PBS. Excess PBS was removed and the phages were eluted by
adding 100 μl of 100 mM triethylamine for 10 min at RT.
The eluted phage suspension was neutralized with 50 μl of 1
M Tris-HCl pH 7.4, then digested 15 min at RT with trypsin
by adding 1.5 μl of 0.1 M CaCl2 and 15 μl of 10 mg/ml
TPCK-treated trypsin (Sigma). 1 ml of a 37°C exponentially
growing Cmax5αF' strain in 2xYT was infected with 40 μl of
trypsin-treated phages, incubated 30 min at 37°C without
shaking, then plated on a 15 cm round Petri dish (LB, 100
μg/ml ampicillin, 1% glucose). After overnight incubation at
37°C, bacteria were recovered from the plate and used to
prepare a new stock of phages using KM13 helper phage.
1011-1012 phages of this stock were used for the next round
of selection.
Periplasmic and cytoplasmic screening
For periplasmic screening, phages from round 3 were used to
infect the non-suppressive strain HB2151. Individual clones
were tested for scFv expression by ELISA on antigen-coated
96-well microtiter plates as described [67]. For cytoplasmic
screening, plasmid was prepared from the pool of bacteria of
the 2nd or 3rd selection round, digested with NcoI and NotI
enzymes, and the 750 bp band was cloned in NcoI-NotI
digested and dephosphorylated plasmid pET23NN. Ligation
was transformed in C-Max5αF', plated on LB with 100 μg/ml
ampicillin and incubated for 16 h at 37°C. Cells were
scrapped and the plasmid DNA prepared and used to trans-
form chemically competent BL21(DE3)pLysS. Individual
clones were grown in a 96-well microtiter plate containing
100 μl of 2xYT, 100 μg/ml of ampicillin with vigorous shak-
ing at 37°C until OD600nm reached 0.6. IPTG was added to
0.4 mM final and the microtiter plate incubated for 16 h at
24–30°C with vigorous shaking in a humidified atmos-
phere. After centrifugation, cells were resuspended in 100 μl
of 50 mM Tris-HCl pH7.5, 5 mM EDTA, freeze/thawed and
incubated 1 h on ice. MgCl2 was added up to 10 mM and the
DNA was digested with 10 μg/ml of DNAseI. 5–20 μl were
used in an ELISA on an antigen-coated 96-well microtiter
plate (Nunc Maxisorp). Revelation was done using 9E10
monoclonal antibody followed by an HRP conjugated anti-
mouse IgG antibody.
Purification of scFv
scFvs cloned in plasmid pET23NN were purified from the
cytoplasm of BL21(DE3)pLysS and purified on a Ni-NTA
column as described for the parental scFv13R4 [26].
Cell transfection and immunofluorescence
HeLa cells were maintained in Dulbecco's modified
Eagle's tissue culture medium (DMEM; Invitrogen) sup-
plemented with L-glutamine (2 mM), penicillin (100 IU/
ml), streptomycin (25 μg/ml) and 10% heat-inactivated
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fetal calf serum at 37°C in a humidified 5% CO2 atmos-
phere. Transient transfection was carried out with the
TransFectin lipid reagent (Bio-Rad, Hercules, CA, USA)
according to the manufacturer's instructions. Cells were
seeded on coverslips in 6-well plates at 2.5 × 105 cells/well
the day before transfection. 1 μg DNA and 2 μl of reagent
diluted in 100 μl of DMEM were mixed and left at room
temperature for 20 min. Cells were grown at 37°C for 24
h after addition of the mixture. The expressed GFP-tagged
proteins were visualized after fixation of the transfected
cells with 4% paraformaldehyde in PBS during 45 min at
room temperature. After extensive wash with PBS, cells
were dried and mounted with Fluoromount-G (Southern-
Biotech, Birmingham, UK). The processed cells were
examined with a Zeiss Axioplan fluorescence microscope
equipped with an Olympus DP50 camera. Images were
collected with a Zeiss 40× plan-neofluar objective and
processed using Adobe Photoshop 5.5. For figure 8, HeLa
were transfected with anti-histones clone 5 fused to the
dsRed-monomer GFP, fixed as above and permeabilized
with Triton ×-100 (0.2%, 5 min). The microtubule net-
work was revealed with the 2F12C scFv (Table 2) at 3 μg/
ml using the 9E10 anti-myc and an Alexa Fluor 488 anti-
mouse IgG antibody. Cells were observed by confocal
microscopy (×63).
List of abbreviations
CAM : chloramphenicol;
CAT : chloramphenicol acethyl transferase;
CDR3 : complementary determining regions 3;
GFP : Green Fluorescent Protein;
H3 : heavy chain CDR3;
IF : Immunofluorescence;
K3 : κ light chain CDR3;
L3 : λ light chain CDR3;
Intrabodies, Intracellular antibodies; 
scFv : Single-chain Fv fragment.
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Additional File 1
Amino acid distribution in CDR3s. Plot of the amino acid distribution 
in the collected database of human CDR3 sequences (Yellow bars) and 
encoded by the spiked oligonucleotides (Red bars). The values for the oli-
gonucleotides are predicted from the degeneracy (see additional file 2: 
Sequences of the spiked oligonucleotides used to introduce the random 
CDR3 loops). Stop codons are noted *. H3_n_p is the pth amino acid of 
the n amino acid long VH CDR3 loops. K3_n_p and L3_n_p are the fre-
quencies for the light chain CDR3 from, respectively, κ and λ classes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-7-81-S1.pdf]
Additional File 2
Sequences of the spiked oligonucleotides used to introduce the random 
CDR3 loops. H3_n = n amino acid long VH CDR3 loop; K3_n = n amino 
acid long VL κ CDR3 loop; L3_n = n amino acid long VL λ CDR3 loop. 
For the degenerated positions, the percentages of the 4 bases are given as 
N(A/C/G/T)
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-7-81-S2.pdf]
Double staining of HeLa cells using an intrabody and by immunofluorescenceFig r 8
Double staining of HeLa cells using an intrabody and 
by immunofluorescence. HeLa cells were transfected 
with anti-histones clone 5 (Figure 6) fused to the dsRed-
monomer GFP. Microtubules were revealed in the trans-
fected cells by IF using the anti-tubulin scFv 2F12C (Table 2). 
Cells were observed at the appropriate wavelength to visual-
ize: (A) 2F12C scFv (microtubules alone); (B) clone 5 intra-
body (histones alone); (C) 2F12C and clone 5 (both 
microtubules and histones); (D) as C plus nucleus staining 
with DAPI.
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